Axim Biotechnologies Inc., a Nevada corporation, is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, genetically controlled botanical products, and extraction and purification of cannabinoids technologies based on our proprietary technologies. We believe to be setting the standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living. Our common stock is traded on the OTCQB under the symbol “AXIM.”
Company profile
Ticker
AXIM
Exchange
Website
CEO
John W. Huemoeller
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AXIM INTERNATIONAL INC.
SEC CIK
Corporate docs
Subsidiaries
Sapphire Biotech, Inc. ...
IRS number
274092986
AXIM stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
DEF 14C
Information statement
21 Sep 23
PRE 14C
Preliminary information
31 Aug 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
EFFECT
Notice of effectiveness
12 Jun 23
Latest ownership filings
4/A
JOHN WALTER HUEMOELLER II
19 Mar 24
4
Catalina Valencia
19 Mar 24
4
Blake Schroeder
19 Mar 24
4
Robert L Cunningham
19 Mar 24
4
Timothy Richard Scott
19 Mar 24
4
Peter O'Rourke
19 Mar 24
4
ROBERT MALASEK
19 Mar 24
4
JOHN WALTER HUEMOELLER II
19 Mar 24
3
Kurt Phinney
30 May 23
144
Notice of proposed sale of securities
7 Oct 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.22 k | 23.22 k | 23.22 k | 23.22 k | 23.22 k | 23.22 k |
Cash burn (monthly) | 24.76 k | 11.71 k | 196.18 k | 684.74 k | 88.17 k | 113.80 k |
Cash used (since last report) | 147.25 k | 69.64 k | 1.17 mm | 4.07 mm | 524.35 k | 676.77 k |
Cash remaining | -124.03 k | -46.42 k | -1.14 mm | -4.05 mm | -501.13 k | -653.55 k |
Runway (months of cash) | -5.0 | -4.0 | -5.8 | -5.9 | -5.7 | -5.7 |
Institutional ownership, Q3 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 500.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Massmutual Trust Co FSB | 500.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Scott Timothy Richard | Convertible Note Common Stock | Grant | Acquire A | No | No | 1 | 35,000 | 35.00 k | 4,500,000 |
15 Mar 24 | Peter O'Rourke | Convertible Note Common Stock | Grant | Acquire A | No | No | 1 | 35,000 | 35.00 k | 4,500,000 |
15 Mar 24 | Malasek Robert | Convertible Note Common Stock | Grant | Acquire A | No | No | 1 | 53,500 | 53.50 k | 3,475,000 |
15 Mar 24 | Huemoeller John Walter Ii | Convertible Note Common Stock | Grant | Acquire A | No | No | 250000 | 1 | 250.00 k | 42,500,000 |
15 Mar 24 | Robert L Cunningham | Convertible Note Common Stock | Grant | Acquire A | No | No | 1 | 35,000 | 35.00 k | 4,500,000 |